Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Novel Peptide Therapeutics for Bone Regeneration

The University of Western Ontario - Industry Liaison
Suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration.

Mechanism of action

Nucleation of bone mineral crystals via specific BSP peptide domains that mediate tight and specific binding to collagen, the structural protein of bone.

Full description

Key Areas: Drug Delivery, Tissue Engineering, Complex Fractures, Spinal Fusions, Bone Grafts, Bone Defects, Osseous Integration of Dental and Orthopedic implants

DESCRIPTION OF THE INVENTION: The present invention comprises a suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration. Researchers at the University of Western Ontario have identified BSP peptide sequences responsible for the nucleation of bone mineral crystals and were also able to pinpoint the region that mediates tight and specific binding to collagen, the structural protein of bone. Such collagen binding peptides are clinically valuable, as they could be used effectively as vehicles for local drug delivery and, in addition, have the potential to act as therapeutics to treat a wide variety of disorders of collagen type I-expressing tissues, including bone, dentin, skin, tendon, and periodontal
ligament.

BACKGROUND: The worldwide orthopedic industry is estimated at over US$13bn, with a projected annual growth rate of 8-10%. While the market is largely captured by medical devices and implants, there is a significant growth opportunity for drug therapeutics to promote bone repair, either as a stand alone therapy or to be used in conjunction with hospital products and devices. The biologics approach to the orthopedics field is one of the fastest-growing segments within the marketplace with an average growth rate of between 15% and 20%.

Bone sialoprotein collagen-binding peptides are ideal drug leads. In the shorter term, the value of these peptides lies in their collagen binding properties that would allow them to be used as drug delivery vehicles for the local delivery and incorporation of specific bioactive therapeutics into soft tissues containing Type I collagen (i.e. skin, tendon and ligament). In the longer term, these peptides hold promise as single agents, or in combination with bone morphogeneic proteins (BMP’s), for a number of therapeutic applications related to the promotion of mineral formation in hard tissues (bone and dentin).

POTENTIAL ADVANTAGES/USES: This technology presents a unique opportunity for a pharmaceutical or biotechnology partner to build on proprietary proof of principle findings, and on years of UWO inventors’ expertise in the field, to develop a novel, safe and effective treatment approach to the medical challenge of bone repair, with applications in tissue engineering, complex fractures, spinal fusions, bone grafts, bone defects due to the removal of tumors, and osseous integration of dental and orthopedic implants.

MARKET OPPORTUNITY:

  • tissue engineering
  • bone and connective tissue formation and repair
  • rheumatoid arthritis
  • spinal fusion
  • local drug delivery
 

Reference Number: UWO-AE-016 

Development status

Preclinical

Patent information

PCT patent application published as WO 2005/082941A1.

Type of business relationship sought

The technology is available for licensing; a collaborative research approach involving the inventors is welcome.

Partnering consultation free of charge
Biomarkers for sepsis and infectious diseases
Need competitive intelligence information
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us